Week in review: Netflix feature, reproxalap relief, blind spot

Coherus has acquired commercial U.S. rights for a ranibizumab biosimilar. Swiss-based Bioeq will still be responsible for filing an FDA biologics license for FYB201, which thus far has posted promising phase 3 outcomes in patients with wet AMD. The product is expected to launch in the United States in 2021. Coherus Bioscience, NIH

“He’s missing both copies of the RPE65 gene. He will eventually go completely blind,” reveals a voice in the trailer for Unnatural Selection, a new Netflix documentary about gene-editing technologies. The series, in part, chronicles the battle Jackson Kennedy and his family faced to obtain genetic testing and insurance coverage for the gene therapy agent Luxturna. The 10-year-old was eventually received the $850,000 drug in 2018. Netflix

Reproxalap significantly relieves allergic conjunctivitis symptoms and signs, according to expanded results from a recent trial. Seventy patients with ocular allergies were dosed before entering an environmental exposure chamber. Reproxalap outperformed the vehicle in reducing ocular itching, redness and tearing. Next steps include the initiation of another placebo-controlled phase 3 trial in early 2020. Aldeyra Therapeutics

Car drivers may have one less blind spot to worry about, thanks to 14-year-old Alaina Gassler. The teenager designed an ingenious projector-based device that renders the pesky A-frame pillar in cars nearly invisible. Her prototype won the $25,000 grand prize at the Broadcom MASTERS national science and engineering competition. Her next goal? Selling her idea to Tesla. “I feel like my project would be something they’d be interested in," Gassler said, adding that she plans to incorporate LCD screens to her next prototype to improve image quality. Popular Mechanics, Society for Science